Immunologic Therapy with Cadi-05 for the Treatment of Advanced Melanoma

Paul J. Mosca MD, PhD  
*Lehigh Valley Health Network*

Suresh G. Nair MD  
*Lehigh Valley Health Network, suresh.nair@lvhn.org*

Susan K. Ayre RN, MA  
*Lehigh Valley Health Network, Susan_K.Ayre@lvhn.org*

Wenjing Shi RN, MS  
*Lehigh Valley Health Network*

Sherrine Eid MPH  
*Lehigh Valley Health Network, Sherrine.Eid@lvhn.org*

See next page for additional authors

Follow this and additional works at: https://scholarlyworks.lvhn.org/medicine  
Part of the [Medical Immunology Commons](https://scholarlyworks.lvhn.org/medicine), and the [Oncology Commons](https://scholarlyworks.lvhn.org/medicine)

**Published In/Presented At**


This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.
Authors
Paul J. Mosca MD, PhD; Suresh G. Nair MD; Susan K. Ayre RN, MA; Wenjing Shi RN, MS; Sherrine Eid MPH; Shantu Amin PhD; Dhimant Desai PhD; Joseph J. Drabick MD, FACP; Bakulesh M. Khamar MD; Arati Sharma PhD; Svetomir N. Markovic MD; and Gavin P. Robertson PhD

This poster is available at LVHN Scholarly Works: https://scholarlyworks.lvhn.org/medicine/67
Immunologic Therapy with Cadi-05 for the Treatment of Advanced Melanoma

Paul J. Mosca, MD, PhD,1 Suresh G. Nair, MD,1 Susan K. Ayre, RN, MA,1 Wenjing Shi, RN, MS,1 Sherrine Eid, MPH,1 Shantu Amin, PhD,2 Dhimant Desai, PhD,2 Joseph J. Drabick, MD,2 Bakulesh M. Khamar, MD,2 Arati Sharma, PhD,2 Svetomir N. Markovic, MD, PhD,1 Gavin P. Robertson, PhD2
1Lehigh Valley Health Network, Allentown, Pennsylvania; 2Penn State Cancer Institute, Hershey, Pennsylvania; 2Cadila Pharmaceuticals, Ahmedabad, India; 3Mayo Clinic, Rochester, Minnesota

Background
- Cadi-05 is a heat-killed mycobacterial preparation with immunomodulatory properties.
- As a Toll-like receptor agonist, Cadi-05 has been postulated to have antineoplastic activity.

Purpose
- The primary objective of this study was to evaluate the safety and toxicity of Cadi-05 monotherapy in the treatment of advanced melanoma patients.

Experimental Design
- 12 patients with stage IV melanoma and measurable disease were treated with one, two, or three 8-week cycles of intradermal Cadi-05.
- Patient demographics are represented in Table 1 and clinical characteristics in Table 2.
- Patients who tolerated treatment without severe adverse events and did not progress were eligible to receive a maximum of three cycles.
- Clinical and translational endpoints were assessed at baseline and after each cycle.

Table 1. Demographics

<table>
<thead>
<tr>
<th>Clinical Characteristic</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, Years</td>
<td>60</td>
<td>55</td>
</tr>
<tr>
<td>Performance status</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Performance status</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Weight</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>No. of Metastatic Sites</td>
<td>6</td>
<td>7</td>
</tr>
</tbody>
</table>

Table 2. Clinical Characteristics

<table>
<thead>
<tr>
<th>Clinical Characteristic</th>
<th>No. of Metastatic Sites</th>
<th>Pretreatment</th>
<th>Cycle 1</th>
<th>Cycle 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiotherapy</td>
<td>9</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Chemotherapy/targeted</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Surgery</td>
<td>7</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Interferon</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Resection/debulking</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Other Therapies</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Prior Therapy</td>
<td>7</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

Results
- Ten of 12 patients enrolled completed at least one cycle of treatment; two patients who failed to complete a single cycle did so because of complications related to disease progression.
- One patient experienced grade 3 toxicity related to treatment; no other patients had grade 3 or higher toxicity.
- There were no objective clinical responses.
- Mixed responses were observed in some patients with regression of one or more lung lesions despite progression elsewhere (Fig. 1).
- One patient developed vitiligo of the treated extremity (Fig. 2). Median follow-up was 6.5 months. Mean survival was 11.9 months (95% CI [5.8, 18.0]), and median survival was 6.7 months (95% CI [3.5, 16.0]).
- Prolonged survival was noted in patients who underwent prior dose IL-2 treatment (20.7 months 95% CI [10.2, 31.0]2 versus 5.6 months 95% CI [3.9, 7.38], p = 0.03) (Fig. 3).
- Seven evaluable patients exhibited a decrease in CD4+FoxP3+ regulatory T cell frequency following one cycle of treatment (Fig. 4).

Conclusions
- Cadi-05 is well tolerated in patients with advanced melanoma, but no objective responses were observed in this small single-arm study.
- Cadi-05 appears to decrease regulatory T cell frequency and thus may have desirable immunologic effects as an adjuvant agent in the treatment of advanced melanoma.

Supported by grants from the Dorothy Rider Pool Health Care Trust and the Penn State Cancer Institute.